SK bioscience Co., Ltd.
- Country
- 🇰🇷South Korea
- Ownership
- Public, Subsidiary
- Established
- 2018-07-02
- Employees
- 1K
- Market Cap
- -
Clinical Trials
10
Trial Phases
2 Phases
Drug Approvals
1
Drug Approvals
SKYCellflu Trivalent Solution for Injection in Prefilled Syringe 0.5ml
- Approval Date
- Jul 7, 2025
- Company
- pharmaniaga marketing sdn bhd
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults
- Conditions
- Japanese Encephalitis Virus Disease
- Interventions
- Biological: GBP560-ABiological: GBP560-BBiological: Normal Saline (Placebo)
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- SK Bioscience Co., Ltd.
- Target Recruit Count
- 402
- Registration Number
- NCT06680128
- Locations
- 🇦🇺
Nucleus Network - Brisbane (Q Pharm), Brisbane, Australia
🇦🇺Nucleus Network - Melbourne, Melbourne, Australia
🇳🇿New Zealand Clinical Research, Christchurch, Central City, New Zealand
A Blood Collection Study to Assess the Immunogenicity of Nationally Authorized Homologous COVID-19 Booster Vaccines Among Adult Vaccinees.
- Conditions
- COVID-19
- First Posted Date
- 2023-02-02
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- SK Bioscience Co., Ltd.
- Registration Number
- NCT05710289
Immunogenicity and Safety Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine(GBP510) Adjuvanted with AS03 in Adults Aged 18 Years and Older
- Conditions
- COVID-19
- Interventions
- Other: Placebo (Normal Saline)Biological: GBP510 adjuvanted with AS03
- First Posted Date
- 2022-08-15
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- SK Bioscience Co., Ltd.
- Target Recruit Count
- 840
- Registration Number
- NCT05501522
- Locations
- 🇨🇴
CAIMED (Centro de Atención e Investigación Médica), Chía, Cundinamarca, Colombia
🇨🇴Policlínico Social Del Norte, Bogotá, Colombia
🇳🇵Dhulikhel, Kathmandu, Dhulikhel, Nepal
Immunogenicity and Safety Study of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine (GBP510) Adjuvanted With AS03 (COVID-19)
- Conditions
- Covid19
- First Posted Date
- 2021-08-17
- Last Posted Date
- 2024-04-08
- Lead Sponsor
- SK Bioscience Co., Ltd.
- Target Recruit Count
- 4036
- Registration Number
- NCT05007951
- Locations
- 🇰🇷
Korea University Ansan Hostpital, Ansan, Gyeonggi, Korea, Republic of
🇰🇷Ajou university hospital, Suwon, Gyeonggi, Korea, Republic of
🇰🇷Dong-A University Hospital, Busan, Korea, Republic of
Safety and Immunogenicity of a SARS-CoV-2 Vaccine (NBP2001) in Healthy Adults (COVID-19)
- Conditions
- COVID-19 (Healthy Volunteers)
- First Posted Date
- 2021-02-18
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- SK Bioscience Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT04760743
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Bundang, Korea, Republic of
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
- Prev
- 1
- 2
- Next